Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study - Top-Institutions - MDSpire

Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study

  • By

  • Fredy Kahkedjian

  • Jaffer Shah

  • Firas Kreidieh

  • July 1, 2026

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    NYU Langone Hospitals
    NYU Langone Hospitals

    New York, NY

    Key Differentiators

    • Pulmonology
    • Vascular Disease

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Pulmonology
    • Vascular Disease

  • #3

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Pulmonology

  • #4

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Pulmonology

  • #5

    Hospital Universitari Germans Trias i Pujol
    Hospital Universitari Germans Trias i Pujol

    Badalona, Spain

    Key Differentiators

    • Pulmonology

Original Source(s)

Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study

  • by Fredy Kahkedjian, Jaffer Shah, Firas Kreidieh

  • July 1, 2026

Related Content

When one size doesn’t fit all: aciclovir dosing and the obesity challenge

Weight Loss, Comorbidity, and Complications After Single-anastomosis Sleeve Ileal Bypass (SASI): A Systematic Review and Meta-analysis

Nearly Four Million Medicare Beneficiaries Met the Eligibility Criteria in 2023 for the Medicare GLP-1 Bridge